3rd Rare Disease Collaboration Summit

With more than 6,000 rare diseases recognized by the NIH, the market for orphan and ultra-orphan indications represents a major growth area for pharma and biotech companies. But low patient numbers combined with the urgency of unmet medical needs can make standard clinical trial procedures unfeasible.

ExL Pharma’s 3rd Rare Disease Collaboration Summit gives you the tools you need to build lasting partnerships with patient advocacy groups in order to construct more flexible and patient-centric clinical trial protocols and accelerate the regulatory approval of your orphan drug. This event hosts the formation of working group relationships that harness the collective resources of industry and patient advocates, creating a working framework for shaping legislation and convincing regulators. Build best practice outputs that outlive the meeting!

URLs:
Booking http://atnd.it/52637-1
Custom http://atnd.it/52637-2

Prices:
Conference - Early Bird Pricing - Before May 20, 2016: USD 1895.00
Conference - Standard Pricing - After May 20, 2016: USD 2095.00

Speakers: Elizabeth Ottinger, Therapeutics for Rare and Neglected Disease, Carrie Burke, Vtesse Pharma, Kari Rosbeck, Tuberous Sclerosis Alliance, Jeremy Morgan, Sanford Research, Jennifer Farmer, Friedrich's Ataxia Research Alliance, Veronica Miller, Forum for Collaborative HIV Research, David Fajgenbaum, The Pennsylvania Hospital of The University of Pennsylvania Health System, Ashish Sagrolikar, Baxter Healthcare, Rashmi Gopal-Srivastava, Office of Rare Diseases Research - NIH, Patricia Weltin, Rare Disease United Foundation, Jonathan Goldsmith, U.S. Food and Drug Administration (FDA), Diane Berry, Sarepta Therapeutics, Stephen Kagan, Pfizer Inc, Kathleen Sartoris, Bellerophon Therapeutics Inc, May Orfali, Pfizer Inc, Carri Levy, The Balancing Act TV LLC, Steven Peltier, Recordati Corporation, Sharie Haugabook, NCATS/NIH

Category: Conferences | Science, Health & Medicine | Diseases